Subscribe to RSS
DOI: 10.1055/s-2007-970424
© Georg Thieme Verlag KG Stuttgart · New York
Somatostatin Receptor Expression in Peripheral Blood of Type 2 Diabetes Mellitus Patients
Publication History
received 26. 6. 2006
accepted 18. 10. 2006
Publication Date:
20 March 2007 (online)
Introduction
Somatostatin, a peptide hormone released by neurons and secretory cells in the central and peripheral nervous system and in the gastrointestinal tract, has a broad inhibitory effect on the secretion of multiple pituitary, pancreatic and gastrointestinal hormones including growth hormone (GH), insulin and glucagon [1]. In addition, anti-inflammatory effects have been described, but data regarding the role of somatostatin in inflammation are controversial [2]. Effects of somatostatin are mediated through specific membrane somatostatin receptors (SSTR) that form a distinct group in the superfamily of G-protein coupled receptors. To date, five human receptor subtypes have been cloned [3], which can be considered to form two subfamilies, consisting of SSTR2, SSTR3, and SSTR5 making up one family, and SSTR1 and SSTR4 forming the second family [4].
Expression of specific SSTR subtypes has been demonstrated in peripheral blood cells [5], and pro-inflammatory cytokines like tumor necrosis factor alpha (TNF-α) can reduce SSTR expression levels [6]. Population-based studies have demonstrated that subclinical inflammation in the pathogenesis of T2DM is characterized by elevated serum levels of C-reactive protein, interleukin (IL)-6, TNF-α, and other immune mediators [7] [8]. Therefore, we tested the hypothesis that SSTR expression is down-regulated in peripheral blood cells from T2DM patients.
References
- 1 Dasgupta P. Pharmacol Ther. 2004; 102 61-85
- 2 Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Nat Rev Drug Discov. 2003; 2 999-1017
- 3 Meyerhof W. Rev Physiol Biochem Pharmacol. 1998; 133 55-108
- 4 Ueberberg B, Tourne H, Redman A, Walz MK, Schmid KW, Mann K, Petersenn S. Horm Metab Res. 2005; 37 722-728
- 5 Lichtenauer-Kaligis EG, Dalm VA, Oomen SP, Mooij DM, van Hagen PM, Lamberts SW, Hofland LJ. Eur J Endocrinol. 2004; 150 565-577
- 6 Yan S, Li M, Chai H, Yang H, Lin PH, Yao Q, Chen C. J Surg Res. 2005; 123 294-301
- 7 Müller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B, Giani G, Illig T, Thorand B, Kolb H. Diabetologia. 2002; 45 805-812
- 8 Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G. Lancet. 1999; 353 1649-1652
- 9 Livak KJ, Schmittgen TD. Methods. 2001; 25 402-408
- 10 Frystyk J, Skjaerbaek C, Vestbo E, Fisker S, Orskov H. Diabetes Metab Res Rev. 1999; 15 314-322
- 11 Park S, Sohn S, Kineman RD. J Endocrinol. 2004; 180 369-378
- 12 Reichlin S. N Engl J Med. 1983; 309 1495-1501
Correspondence
K. Kempf
German Diabetes Clinic · German Diabetes Center · Leibniz Institute at Heinrich-Heine-University Düsseldorf
Auf'm Hennekamp 65
40225 Düsseldorf
Germany
Phone: +49/211/338 26 47
Fax: +49/211/338 26 53
Email: Kerstin.Kempf@ddz.uni-duesseldorf.de